ALNEV — Neovacs SA Balance Sheet
0.000.00%
- €0.01m
- €0.14m
- €0.29m
- 9
- 100
- 10
- 29
Annual balance sheet for Neovacs SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | FAS | — | FAS | FAS | FAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 10.1 | 33.1 | 6.76 | 0.887 | 0.435 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2.83 | 1.6 | 1.81 | 2.78 | 1.95 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 13.1 | 34.8 | 9.07 | 3.81 | 2.48 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.255 | 0.506 | 0.511 | 0.527 | 0.415 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 13.5 | 48.6 | 55.3 | 52.6 | 22.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.42 | 4.65 | 5.12 | 3.71 | 3.84 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 2.51 | 4.65 | 5.13 | 3.72 | 4.01 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 11 | 43.9 | 50.2 | 48.8 | 18.1 |
| Total Liabilities & Shareholders' Equity | 13.5 | 48.6 | 55.3 | 52.6 | 22.1 |
| Total Common Shares Outstanding |